3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Esophageal Neoplasms
1
Desmoid Tumors
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Paclitaxel
69
Bevacizumab
62
Carboplatin
53
pembrolizumab
46
olaparib
32
Specimen Handling
27
Gemcitabine
27
Cyclophosphamide
26
Magnetic Resonance Spectroscopy
24
liposomal doxorubicin
22
Cisplatin
21
niraparib
20
Taxes
18
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
12
Fulvestrant
12
Disulfides
12
Oxaliplatin
10
mirvetuximab soravtansine
9
durvalumab
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
Blood Specimen Collection
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
High-Intensity Focused Ultrasound Ablation
×
1 year
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled